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The objectives of this study were to test the efficacy and safety of planned exposure to porcine reproductive
and respiratory syndrome virus (PRRSV) in protecting naı¨ve and previously exposed pigs against PRRSV
challenge and to gain information on the dose of PRRSV necessary to induce a protective immune response.
Fifty 2-week-old pigs were randomly assigned to one of five groups: a group exposed to a low dose of autogenous
PRRSV vaccine (the L-VAC group), a group exposed to a high dose of autogenous vaccine (the H-VAC group),
a group exposed to a low dose of a heterologous PRRSV strain (strain SDSU73) prior to planned exposure (the
SDSU73-L-VAC group), a group exposed to a high dose of a heterologous PRRSV strain (strain SDSU73) prior
to planned exposure (the SDSU73-H-VAC group), and a control group. All groups were challenged with PRRSV
VR2385 5 weeks after the planned exposure. Necropsy was done 2 weeks after the PRRSV challenge. The
H-VAC, SDSU73-L-VAC, and SDSU73-H-VAC groups had significantly (P < 0.05) less severe clinical disease
(sneezing, respiratory scores, and weight gain), significantly (P < 0.05) less severe macroscopic and micro-
scopic lung lesions, and significantly (P < 0.05) lower numbers of PRRSV genomic copy numbers in their sera
compared to the results for the control group. Planned exposure to live PRRSV can be used as an inexpensive
and effective way to decrease the severity of PRRSV-induced disease following subsequent challenge.
A syndrome known as porcine reproductive and respira-
tory syndrome (PRRS) emerged simultaneously in Europe
and North America at the beginning of the 1990s (11, 22).
The “Lelystad virus” was isolated from pigs with PRRS in The
Netherlands in 1991 (22). A similar virus was identified in the
United States in 1992 (2, 4) and was subsequently found to be
closely related to the European isolate, and both viruses were
designated porcine reproductive and respiratory syndrome vi-
rus (PRRSV). PRRSV is a small, enveloped, positive-sense,
single-stranded RNA virus classified in the order Nidovirales,
family Arteriviridae, genus Arterivirus (3). PRRSV is associated
with reproductive failure in adults and is characterized by mid-
to late-term abortions, increased numbers of mummified fe-
tuses, early embryonic death, and infertility (14). In growing
pigs, PRRSV infection is associated with respiratory disease
and is characterized by labored breathing, sneezing, fever, and
increased susceptibility to bacterial diseases, such as those
caused by Streptococcus suis (21). PRRSV isolates vary anti-
genically, genetically, and in their virulence properties (9, 13).
North American PRRSV isolates have been found to be more
virulent than the Lelystad PRRSV strain when they are com-
pared in the growing pig model (7, 8). It is also clear that North
American PRRSV isolates vary in their virulence (9). The
degree of immunity generated against heterologous isolates
based on genetic or antigenic characteristics is still poorly un-
derstood.
PRRSV-induced abortion storms affecting 10 to 25% of the
breeding-age females in a herd are not uncommon (6), and the
losses due to the postweaning form of the disease can be
similarly severe and financially devastating. It has been esti-
mated that the economic impact of PRRSV in the United
States is approximately $66.75 million for breeding herds and
$493.57 million for growing pigs (16). Strategies that can be
used to control PRRSV include the elimination of PRRSV
through partial de- and repopulation, herd closure followed by
the replacement and introduction of naı¨ve pigs, segregated
early weaning, multisite production, and parity segregation
strategies. Vaccination approaches with modified live virus
products have proved successful in experimental settings; how-
ever, failures have been reported in the field (10) and vaccine-
like isolates of PRRSV have been recovered from cases of
reproductive failure in breeding herds or respiratory disease in
growing pigs, suggesting that reversion to virulence may occur
under some circumstances (17).
Veterinarians are increasingly relying on natural or planned
exposure to the farm-specific strain of PRRSV to induce long-
term immunity in the herd. Planned exposure in the past has
most commonly been done by putting infected pigs in contact
with naı¨ve breeding stock or feeding naı¨ve breeding stock
aborted fetuses or tissues from infected pigs. These approaches
may be unreliable in getting the targeted population consis-
tently infected in a timely manner. Because of this, some vet-
erinarians have initiated the injection of serum from PRRSV-
infected pigs into breeding-age animals to ensure exposure to
the resident strain (1, 20). This procedure has not been well
described or tested in a controlled setting for safety or efficacy.
The main objective of this study was to test the efficacy and
safety of a live autogenous PRRSV vaccine to protect naı¨ve or
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previously exposed pigs against PRRSV challenge. The second
objective was to gain more information on the PRRSV dose
that is able to induce a protective immune response yet mini-
mal disease.
MATERIALS AND METHODS
Animals. Fifty-four 2-week-old, segregated, early weaned, crossbred pigs were
purchased from a herd free of PRRSV and Mycoplasma hyopneumoniae, as
determined on the basis of regular serological testing. The sows in this herd were
routinely vaccinated for swine influenza virus (SIV) and porcine parvovirus
(PPV).
Experimental design, housing, and feeding. The experimental design of the
study is summarized in Table 1. The pigs were included in one of five groups: a
group exposed to a low dose of autogenous PRRSV vacccine (the L-VAC
group), a group exposed to a high dose of autogenous homologous vaccine (the
H-VAC group), a group exposed to a low dose of a heterologous PRRSV strain
(strain SDSU73) prior to planned exposure (the SDSU73-L-VAC group), a
group exposed to a high dose of a heterologous PRRSV strain (strain SDSU73)
prior to planned exposure (the SDSU73-H-VAC group), and a control group.
On the day of delivery, the pigs were randomly assigned to five groups with 10
pigs and one group with four pigs (serum donor pigs). All groups were housed in
separate rooms in pens (2 by 2.5 m) on the floor and equipped with one nipple
drinker and one self-feeder. The experimental protocol was approved by the
Iowa State University Institutional Animal Care and Use Committee.
PRRSV isolates. PRRSV isolate VR2385 was recovered from a 160-sow herd
in southwestern Iowa that had experienced severe respiratory disease in 3- to
16-week-old pigs and high numbers of late-term abortions in 1991 (8). VR2385
has a restriction fragment length polymorphism pattern of 1-3-4. Highly virulent
isolate SDSU73 was recovered from a sow herd that experienced a severe
epidemic of atypical PRRS in 1996 (14). The restriction fragment length poly-
morphism pattern of SDSU73 is 1-4-4. The nucleic acid homology between
SDSU73 and the VR2385 is 76%, based on sequencing of open reading frame 5
(ORF5).
Serology. Blood samples were collected on the arrival of the pigs at the
research facility (when they were 2 weeks of age) and weekly thereafter through-
out the duration of the study.
(i) PRRSV ELISA. The serum samples taken on the arrival of the pigs at the
research facility, on the day of VR2385 serum injection, on the day of VR2385
challenge, and at necropsy were tested for the presence of antibodies to PRRSV
by a commercial PRRSV enzyme-linked immunosorbent assay (ELISA; Herd-
Chek PRRS virus antibody test kit 2XR; IDEXX Laboratories, Inc., Westbrook,
MA). Samples were considered positive if the sample-to-positive ratio was 0.4 or
greater.
(ii) VR2385-specific PRRSV FFN assay. A fluorescent focus neutralization
(FFN) assay for determination of the amount of VR2385-specific neutralizing
antibodies was done with sera collected on the day of VR2385-positive serum
injection (5 weeks after SDSU73 inoculation) and 5 weeks later, on the day of
VR2385 challenge, according to the protocols routinely performed at the Vet-
erinary Diagnostic Laboratory at Iowa State University.
(iii) Miscellaneous serology. Serum samples collected on the arrival of the pigs
at the research facility and at the termination of the study were tested by a PCV2
ELISA based on the recombinant ORF2 capsid protein of PCV2 (15). Samples
were considered positive if the calculated sample-to-positive ratio was 0.2 or
greater. The serum samples taken on the arrival of the pigs at the research facility
and at necropsy were tested for the presence of antibodies to PPV, SIV H1N1,
and SIV H3N2 by hemagglutination inhibition assay.
PRRSV quantification. The extraction of RNA from the sera collected on
the day of PRRSV inoculation and at 7 and 14 days after PRRSV inoculation
was performed by using a QIAamp viral RNA mini kit (Qiagen, Valencia,
CA). Primer-probe combinations specific for ORF7 of the North American
PRRSV strain (primer PRRSORF7F [TGTCAGATTCAGGGAGRATAAG
TTAC], primer PRRSORF7R [ATCARGCGCACAGTRTGATGC], and
probe PRRSORF7P [FAM-TGTGGAGTTYAGTYTGCC, where FAM is
6-carboxyfluorescein]) and the ORF7 of the European PRRSV (primer LELYRTF
[GCTGAAGATGACRTYCGGCA], primer LELYRTR [GCAGTYCCTGC
GCCTTGAT], and probe LELYRTP [VIC-TGCAATCGATYCAGAC])
were used (18). The PCR mixture consisted of 5 l RNA template and 20 l
PCR master mixture. The master mixture contained 0.35 l of the mixture
from the QuantiTect probe reverse transcriptase PCR kit (Qiagen) with the
magnesium chloride concentration adjusted to 6 mM; 025 l (1.25 U) of
HotStar Taq (Qiagen); 800, 800, and 275 nM forward primers, reverse prim-
ers, and detection probes for the North American strain, respectively; and
400, 400, and 100 nM forward primers, reverse primers, and detection probes
for the European PRRSV strain, respectively. Each reaction mixture included
five progressive 1:10 dilutions of a known genomic copy number of PRRSV
that served to generate a standard curve. Each plate was run in a sequence
detection system (GeneAmp 7900; Applied Biosystems, Foster City, CA)
under company-specific conditions (30 min at 50°C and 15 min at 95°C,
followed by 35 cycles of 15 s at 94°C and 60 s at 60°C).
Serum donor pigs. Four serum donor pigs were inoculated intranasally at 3
weeks of age with 2 ml of VR2385 at 105 50% tissue culture infective doses
(TCID50s). At 7 days postinoculation, blood was drawn and was confirmed to be
positive for PRRSV nucleic acids by reverse transcriptase PCR. The pigs were
killed, and blood was collected for serum injection. Within 30 min, the blood was
transported to the laboratory on ice, centrifuged, and stored at 80°C until
further use.
Inoculation of pigs with a heterologous isolate of PRRSV. At 3 weeks of age,
5 weeks before VR2385-positive serum injection, the pigs in the SDSU73-L-
VAC and SDSU73-H-VAC groups were inoculated intranasally with 2 ml of
passage 2 of SDSU73 at 105 TCID50s (Table 1).
PRRSV-positive serum injection. On the day of planned exposure by serum
injection, the donor serum was thawed and the amount of PRRSV genomic
copies was determined by quantitative real-time PCR. During the time period
necessary for real-time PCR testing, the sera were stored at 4°C on ice. Serum
from one pig that contained approximately 2.18  106 PRRSV copies and that
was negative for PRRSV-specific antibodies was selected for use for serum
injections.
One gram ceftiofur sodium (Naxcel; lot number 1253NX; Pharmacia & Up-
john Company, Kalamazoo, MI) was dissolved in 250 ml sterile saline. The
ceftiofur sodium-saline solution was used to dilute the serum. Two solutions with
different concentrations were prepared: 30 ml was prepared to contain approx-
imately 105 virus particles in 2 ml, and another 30 ml was prepared to contain
approximately 102 virus particles in 2 ml. The final serum-saline-ceftiofur sodium
mixtures were kept on ice for approximately 30 min until the use of the product
as an injectable autogenous live vaccine. All pigs except the controls received 2
ml of the autogenous vaccine intramuscularly in the right neck. The pigs in the
L-VAC and SDSU73-L-VAC groups received approximately 102 PRRSV copies,
and the pigs in the H-VAC and SDSU73-H-VAC groups received approximately
105 PRRSV copies (Table 1). After injection, the amount of viable PRRSV in the
vaccine preparations was determined by titration and was found to be 104.17
TCID50s in the high-dose groups and 102.17 TCID50s in the low-dose groups.
Postvaccination PRRSV challenge. Five weeks after the injection with the
live autogenous vaccine, all pigs were challenged intranasally with 2 ml
PRRSV strain VR2385 at a dose of 104.25 TCID50s. At this time the pigs were
13 weeks old.
Clinical evaluation. The pigs were monitored daily and were scored for the
severity of clinical respiratory disease, with the scores ranging from 0 (normal) to
6 (severe dyspnea and abdominal breathing) (8). In addition, the pigs were
evaluated daily for clinical signs and behavioral changes, including sneezing and
lethargy. Rectal temperatures were recorded daily. The pigs were weighed
weekly until PRRSV challenge and at necropsy.
TABLE 1. Experimental design used to test the efficacy of planned
injection of PRRSV to protect pigs against subsequent
exposure to PRRSV
Groupa Designation Inoculum at3 wks of age
Content of serum
injected at 8 wks
of ageb
1 L-VAC None Low
2 H-VAC None High
3 SDSU73-L-VAC SDSU73c Low
4 SDSU73-H-VAC SDSU73c High
5 Controls None None
a Each group had 10 pigs. The pigs in all groups were inoculated with strain
VR2385 at 13 weeks of age.
b PRRSV genomic copy numbers were determined by quantitative PCR. Low,
approximately 102 PRRSV strain VR2385 genomic copies per 2 ml; high, ap-
proximately 105 PRRSV strain VR2385 copies per 2 ml.
c Groups 3 and 4 received approximately 105 TCID50s of SDSU73 in a 2-ml
volume.
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Necropsy. Necropsies were performed 14 days after PRRSV challenge, when
the pigs were 15 weeks of age. The total amount of lung affected by macroscopic
lesions (ranging from 0 to 100% of the affected lung) was estimated, and the
lungs were insufflated with fixative, as described previously (8). Sections of the
lymph nodes (superficial inguinal, mediastinal, tracheobronchial, mesenteric),
tonsil, thymus, ileum, kidney, colon, spleen, and liver were collected at necropsy;
fixed in 10% neutral-buffered formalin; and routinely processed for histological
examination.
Histopathology. Microscopic lesions were evaluated in a blinded fashion. Lung
tissue sections were scored for the presence and the severity of interstitial
pneumonia, with the scores ranging from 0 (normal) to 6 (severe diffuse) (8).
Sections of the heart, liver, kidney, ileum, colon, lymph nodes, spleen, and tonsil
were evaluated for the presence of lymphohistiocytic inflammation and were
scored from 0 (none) to 3 (severe) (8).
Statistical analysis. Summary statistics were calculated to assess the overall
quality of the data. Analysis of variance (ANOVA) was used for cross-sectional
assessment of the average daily weight gain and nonrepeated continuous mea-
sures. The significance level was a P value of 0.05; pairwise testing by use of the
Tukey-Kramer adjustment was used to identify the groups that were different. In
order to summarize and simplify the clinical observations, response feature
analysis and the chi-square test were used. The clinical scores for each pig were
reduced to one weekly mean score, and the resulting values were subject to
statistical analysis. Nonrepeated measures of the necropsy and the histopathol-
ogy data were assessed by use of the nonparametric Kruskal-Wallis ANOVA. If
a nonparametric ANOVA test was significant (P  0.05), then Wilcoxon tests
were used to assess the differences for pairs of groups. Differences in incidence
were evaluated by using Fisher’s exact test.
RESULTS
PRRSV-specific IgG antibodies. On their arrival at the re-
search facilities, all pigs were negative for PRRSV-specific
immunoglobulin G (IgG) antibodies (Fig. 1). At the time of
injection with the live autogenous vaccine, all pigs in the
SDSU73-L-VAC and SDSU73-H-VAC groups, which had
been exposed to SDSU73 5 weeks earlier, had seroconverted
to PRRSV, whereas the PRRSV-naı¨ve groups (the L-VAC,
H-VAC, and control groups) had not. On the day of VR2385
challenge, all groups except the controls had seroconverted to
PRRSV. At the termination of the study, all pigs in all groups
were positive for PRRSV-specific antibodies, as determined by
ELISA (Fig. 1).
Anti-VR2385-specific neutralizing antibodies. On the day of
injection with the live autogenous vaccine, the strain SDSU73-
treated groups had significantly (P  0.003) larger amounts of
neutralizing antibodies compared to those in all other groups
(Fig. 2). On the day of VR2385 challenge, all groups that
received an injection with the live autogenous PRRSV vaccine
had significantly (P  0.001) larger amounts of neutralizing
antibodies than the controls (Fig. 2).
Additional serology. On their arrival at the research facility,
all pigs had some level of passively acquired antibodies to PPV
and PCV type 2 (PCV2), the titers of antibodies to both of
which decayed over time. None of the control pigs serocon-
verted to PPV or PCV2 during the course of the experiment.
At the termination of the experiment, all pigs were negative for
antibodies specific to PPV and PCV2 and for antibodies spe-
cific to H3N2 and H1N1 SIV.
Clinical disease. After injection of the pigs with the live
autogenous PRRSV vaccine, individual pigs in all groups de-
veloped fevers, with their temperatures ranging from 40 to
40.5°C, and had periods of labored breathing. For the 5 weeks
postvaccination, there were no significant differences among
the groups injected with the live autogenous PRRSV vaccine,
as determined by measurement of their respiratory scores and
rectal temperatures. However, the nonexposed controls had
significantly (P  0.0014) higher average daily weight gains
compared to those for the pigs in all other groups that received
the injection of live autogenous PRRSV vaccine. In the period
after challenge with VR2385, there were pigs in all groups that
experienced increased respiratory scores; however, there were
no differences in respiratory scores among the groups. The
rectal temperatures were significantly (P 0.001) higher in the
controls, and the controls had significantly (P  0.05) reduced
average weight gains compared to those for pigs in the groups
that had previously been inoculated with heterologous isolate
SDSU73 and subsequently injected with the live autogenous
PRRSV vaccine containing VR2385 (Table 2).
PRRSV genomic copy numbers in sera. The data on the
PRRSV genomic copy numbers in sera are summarized in
Table 3. There was a significantly (P  0.001) higher inci-
dence of PCR-positive pigs, and on postinoculation days 7
and 14 the PRRSV genomic copy numbers were significantly
(P  0.001) higher in the controls than in all other groups.
Among the controls, 80% of the pigs were positive for
FIG. 1. Anti-PRRSV IgG response as measured by ELISA in the
different treatment groups. Postinoculation day (DPI) 70, SDSU73
inoculation; postinoculation day 35, serum injection; postinoculation
day 0, VR2385 inoculation; postinoculation day 14, necropsy.
FIG. 2. Anti-VR2385-specific neutralizing antibody response in the
controls, pigs inoculated with SDSU73 on postinoculation day (DPI)
70 (SDSU73-VAC groups), and pigs injected with serum on postin-
oculation day 35 (VAC and SDSU73-VAC groups) prior to VR2385
inoculation on postinoculation day 0. Asterisks, significant differences
(P  0.05) between groups on a given day postinoculation.
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PRRSV nucleic acids in serum by real-time PCR on posti-
noculation days 7 and 14.
Macroscopic lesions. The macroscopic lesion data are sum-
marized in Table 4. Macroscopic lung lesions were character-
ized by failure of the lungs to collapse and by mottled tan,
well-demarcated areas of pneumonia. The controls had the
highest mean lung lesion scores, with 34.9%  5.1% of the
lung affected. For all vaccinated groups except the L-VAC
group, the mean gross lung lesion scores were significantly
(P  0.001) lower than those for the control group.
Microscopic lesions. Microscopic lung lesions were typical
of those associated with PRRSV infection and were character-
ized by interstitial pneumonia with alveolar septal thickening
due to type 2 pneumocyte hypertrophy and hyperplasia and the
infiltration of septae with macrophages, necrotizing alveolitis,
and the accumulation of seroproteinaceous fluid in the alveo-
lar spaces. The group mean scores for interstitial pneumonia
are summarized in Table 4. With the exception of the L-VAC
group, the microscopic lung lesion scores were significantly
(P  0.001) lower in the vaccinated groups than in the
control group.
Effect of planned exposure dose. The dose had no effect on
macroscopic or microscopic lung lesions, the average daily
weight gain after challenge, or rectal temperatures after chal-
lenge.
Effect of previous exposure to a heterologous strain. There
was no evidence that neutralizing antibodies to SDSU73 inter-
fered with the development of protective immunity to VR2385.
There were significantly (P  0.01) less severe macroscopic
lung lesions in the strain SDSU73-inoculated pigs. There was
no effect of exposure to SDSU73 on microscopic lung lesions,
average daily weight gain after VR2385 challenge, or rectal
temperature after challenge.
DISCUSSION
The main objective of this study was to test the efficacy and
safety of the live autogenous PRRSV vaccine for the protec-
tion of naı¨ve or previously exposed pigs against homologous
PRRSV challenge in a controlled setting. Under the conditions
of this study, the live autogenous PRRSV vaccine utilized was
effective in partially protecting naı¨ve pigs and pigs previously
exposed to a heterologous PRRSV stain against subsequent
PRRSV challenge, as measured by the decreased length and
levels of viremia and the decreased severity of PRRSV-in-
duced gross and microscopic lesions. This is the first controlled
experiment to have further documented the efficacy of a pro-
cedure that has been used extensively in the field.
On the basis of the macroscopic lung lesion scores, repeated
exposure was more protective than a single exposure. How-
ever, the microscopic lung lesion scores neither completely
reflected the macroscopic lesions scores nor completely sup-
ported cross-protection. The slight discordance of the macro-
scopic lesion scores and the microscopic lesion scores can be
explained by the fact that the macroscopic lesion score ac-
counts for the severity and the extent of lesions, whereas the
microscopic lung lesion score accounts for severity only. For
example, a lesion might be mild but diffuse. This would result
in a low microscopic lesion score but a moderate macroscopic
lesion score.
Fano et al. (5) reported a significant (P  0.05) reduction in
the prevalence of PRRSV antibody-positive pigs 1 year after
they implemented live autogenous PRRSV vaccination of in-
coming gilts in a Mexican swine production system. Similarly,
Hill et al. (9a) reported a marked improvement of sow herd
stability after serum autogenous vaccine interventions, as de-
termined by measurement of the reproductive performance of
the breeding herd and the incidence of viremia in weaned pigs
in the United States. In contrast to those studies, we tested our
protocol under experimental conditions with the growing pig
model.
The use of a live autogenous PRRSV vaccine may be justi-
fied in herds in which currently available commercial modified
live virus PRRSV vaccines have failed. However, those who
use planned exposure must understand the risks. Experiences
TABLE 2. Average daily weight gain from the time of PRRSV
strain VR2385 challenge to the day of necropsy
Group Avg daily wt gain(g)a
L-VAC........................................................................ 986.4  48.6*,**
H-VAC ....................................................................... 954.9  71.5*,**
SDSU73-L-VAC........................................................1,101.6  42.1*
SDSU73-H-VAC .......................................................1,016.1  107.3*
Control ....................................................................... 711.6  67.6**
a Average daily weight gain from 0 to 14 days after PRRSV strain VR2385
inoculation. Values are means  SE. Different symbols (* and **) within the
column indicate significant (P  0.05) differences in group mean values. Values
with both symbols are not significantly different from the other values.
TABLE 3. Incidence of PRRSV genomic copies in serum on day of
PRRSV challenge and days 7 and 14 postinoculation
Group
Incidence (no. of PRRSV-positive pigs/total no. of pigs in
group group mean of log-transformed data  SE) on
postinoculation daya:
0 7 14
L-VAC 0/10 (0.0  0.0) 2/10 (0.6  0.5)* 0/10 (0.0  0.0)*
H-VAC 0/10 (0.0  0.0) 0/10 (0.0  0.0)* 0/10 (0.0  0.0)*
SDSU73-
L-VAC
1/10 (0.2  0.2) 1/10 (0.3  0.3)* 0/10 (0.0  0.0)*
SDSU73-
H-VAC
0/10 (0.0  0.0) 0/10 (0.00  0.0)* 0/10 (0.0  0.0)*
Control 0/10 (0.0  0.0) 8/10 (3.9  0.7)** 8/10 (2.0  0.5)**
a Different symbols (* and **) within a column indicate significant (P  0.001)
differences in group mean values and incidences.
TABLE 4. Comparison of severities of macroscopic and
microscopic lung lesions in PRRSV-infected pigsa
Group (no. of pigs) Macroscopic lunglesion incidence (%)
Microscopic lung
lesion score
L-VAC (10) 20.3  3.1*,** 1.6  0.3*,**
H-VAC (10) 18.2  3.4* 0.7  0.2*
SDSU73-L-VAC (10) 10.0  3.6* 1.1  0.3*
SDSU73-H-VAC (10) 11.6  3.1* 1.4  0.2*
Control (9) 34.9  5.1** 2.7  0.4**
a The range for the macroscopic lung lesion incidence is 0 to 100%; the range
for the microscopic lung lesion score is 0 to 6. Different symbols (* and **) within
a column indicate significant (P  0.001) differences in group mean values and
incidences. Values with both symbols are not significantly different from the
other values.
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from the field document that short-term losses immediately
following the use of the live autogenous product in pregnant
animals are variable but can be substantial (R. Baker, personal
communication). Similarly, there is evidence that under cer-
tain conditions, the commercially approved, live attenuated
PRRSV vaccines can also revert to virulence (17).
Reports of abortion induction in sows previously exposed to
apparently homologous isolates also frequently occur (R.
Baker, personal communication). This may be a consequence
of determining the degree of homology entirely on the basis of
the sequences of ORF5, which may not fully represent anti-
genic diversity or similarity.
Killed autogenous vaccines have also been used in breeding
herds, particularly to booster immunity from previous natural
exposure (M. McCaw, personal communication).
It has been shown that PRRSV-specific antibodies are ef-
fective in reducing PRRSV-associated disease, and some level
of heterologous protection has been demonstrated; however,
the protection appears to be strain specific (12). Osorio et al.
(19) found that a cocktail of PRRSV IgG can confer protective
immunity against PRRSV-induced reproductive failure in gilts.
In contrast, there is also research that supports the idea that
small amounts of antibodies accelerate PRRSV binding and
entrance into macrophages and, subsequently, increase the
incidence of disease (23). Practitioners have expressed concern
that the immunity present in breeding-age animals previously
exposed to an isolate of PRRSV may interfere with the devel-
opment of protective immunity against new isolates (anergy)
that enter the herd and against isolates that are utilized in
updated autogenous live vaccine regimens.
Other risk factors from the use of serum injections for
planned exposure to PRRSV must be considered. One issue is
the risk of the spread of other known and unknown disease
agents which may be present in raw serum. To minimize this
risk, practitioners often request PCR for other agents, such as
porcine circovirus type 2, in aliquots of the serum that they
intend to use and use only those batches in which certain other
agents were not found. It should be pointed out that diagnostic
laboratories typically look for established economically impor-
tant agents. Numerous other agents are potentially present in
these autogenous serum vaccines. Porcine endogenous retro-
viruses, lymphotrophic herpesviruses, teschoviruses, pestivi-
ruses, Chlamydia spp., and a host of other likely candidates
should be considered potential risks. Although the distribution
of these potential pathogens is likely ubiquitous within a herd,
the long-term consequences of the synthetic transmission and
propagation of these other viruses may largely be underappre-
ciated.
The results of this study indicate that planned exposure to
live PRRSV in serum can be used as an inexpensive and
effective way to decrease the severity of PRRSV-induced
disease following subsequent challenge, regardless of
whether the pigs had been previously exposed to a heterol-
ogous strain of PRRSV. However, the success of this pro-
cedure also likely depends on the scenario for the individual
herd. Precautions should be taken to confirm that the serum
does not contain unintended viruses, and the use of mass
serum injections should be monitored closely.
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